Cite this: *Chem. Soc. Rev.*, 2021, 50, 9346

DOI: 10.1039/d1cs90064a

rsc.li/chem-soc-rev

Correction: Antiviral drug discovery: preparing for the next pandemic

Catherine S. Adamson,^a Kelly Chibale,^b Rebecca J. M. Goss,^c Marcel Jaspars,^d David J. Newman^e and Rosemary A. Dorrington^{*f}

Correction for 'Antiviral drug discovery: preparing for the next pandemic' by Catherine S. Adamson *et al.*, *Chem. Soc. Rev.*, 2021, **50**, 3647–3655, DOI: 10.1039/D0CS01118E.

The authors regret that a section of text in the original article was duplicated in error. On page 3650, the following duplicated text should have been deleted: “subsequent nucleosides cannot bind.¹⁶ Nucleos(t)ide analogue inhibitors are administered as prodrugs, which upon cell up-take are metabolized by host and/or viral kinases to their active triphosphate form. Acyclovir 3; an acyclic guanosine analogue (Fig. 2) used to treat Herpes simplex virus (HSV) infection, has high selectivity due to specific phosphorylation by the HSV-encoded thymidine kinase confining activity to virus-infected cells.¹⁶”

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

^a School of Biology, Biomedical Sciences Research Complex, University of St Andrews, St Andrews, KY16 9ST, Scotland, UK

^b Drug Discovery and Development Centre (H3D) and South African Medical Research Council Drug Discovery and Development Research Unit, Department of Chemistry and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch 7701, South Africa

^c School of Chemistry, University of St Andrews, North Haugh, St Andrews, Fife, UK

^d Marine Biodiscovery Centre, Department of Chemistry, University of Aberdeen, Old Aberdeen, AB24 3DT, Scotland, UK

^e Retired Chief, Natural Products Branch, NIH/NCI, Frederick National Laboratory, MD, USA

^f Dept. of Biochemistry and Microbiology, Rhodes University, Makhanda (Grahamstown), South Africa. E-mail: r.dorrington@ru.ac.za